Ionis Pharmaceuticals, Inc. (IONS)

Ionis Pharmaceuticals' stock (IONS) has seen significant positive movement, with its price rising by 169.53% over the last 12 months. In October 2025, Ionis reported positive topline Phase 3 results and increased its 2025 financial guidance. In December 2025, Ionis secured FDA approval for Tryngolza (olezarsen) for familial chylomicronemia syndrome (FCS). In February 2026, Ionis reported strong financial results for the fourth quarter and full year 2025, driven by Tryngolza product sales, but the stock was down on a soft 2026 outlook. In March 2026, the FDA granted Priority Review to Ionis' New Drug Application for zilganersen for Alexander disease. In April 2026, Raymond James initiated coverage on Ionis Pharmaceuticals with an "Outperform" rating and a $104 price target, while insider selling of $78.9 million in shares over the past three months was noted.

There is no specific information available regarding demand seasonality for Ionis Pharmaceuticals' products and services. Demand would likely be driven by disease incidence and diagnosis rather than seasonal patterns.

Ionis Pharmaceuticals, Inc., headquartered in Carlsbad, California, is a biotechnology company specializing in RNA-targeted therapeutics, focusing on antisense therapy, RNA interference, and CRISPR therapeutics. Ionis aims to develop innovative medicines for unmet medical needs, particularly in neurology, cardiometabolic diseases, and other areas of high patient need. Major products include Spinraza® (nusinersen) for SMA, Tegsedi® (inotersen) for hATTR with polyneuropathy, Waylivra® (volanesorsen) for FCS, Qalsody® (tofersen) for SOD1-ALS, Wainua® (eplontersen) for ATTRv-PN, Tryngolza® (olezarsen) for FCS and sHTG, Dawnzera™ (donidalorsen) for HAE, and Zilganersen, which has an FDA PDUFA date set for September 22, 2026 for Alexander disease (AxD).

Ionis Pharmaceuticals, Inc. is headquartered in Carlsbad, California, U.S. The company's products are approved and launched in various regions, including the European Union (EU) for Tryngolza. Its collaborations and drug approvals suggest an international reach for its therapies.

Ionis Pharmaceuticals has established a reputation as a pioneer and leader in RNA-targeted therapeutics, with a mission to invent medicines that improve the lives of people with serious diseases. In the past year, successful execution of its first two independent drug launches, multiple positive data readouts across its pipeline, FDA approvals and priority reviews for its innovative therapies, and strategic partnerships and collaborations have positively impacted its reputation. No significant negative events impacting Ionis Pharmaceuticals' brand reputation in the past year were found.

Ionis Pharmaceuticals' ownership is primarily held by institutional investors, which include major asset management firms and mutual funds. As of early 2025, institutional investors collectively held over 94% of Ionis stock. Major institutional owners include Fidelity Management & Research Company LLC (14.84%), The Vanguard Group, Inc. (10.27%), T. Rowe Price Investment Management, Inc. (10.16%), Capital World Investors (7.77%), BlackRock, Inc. (5.59%), and Wellington Management Group LLP (5.29%).